Biotage AB (publ)'s (STO:BIOT) Popularity With Investors Under Threat As Stock Sinks 26%
Mar 05
Have your own idea? Try our Stock Screener
Swedish (OMX) Clinical Research and Equipment Industry Analysis
UpdatedMar 23, 2025
DataAggregated Company Financials
Companies11
- 7D-2.2%
- 3M-14.8%
- 1Y-4.9%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 2.2%, driven by a pullback from Biotage of 3.4%. On the other hand Attana is actually up 17%. The industry has fallen 4.9% in the last year. As for the next few years, earnings are expected to grow by 29% per annum.
Industry Valuation and Performance
Has the Swedish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 24 Mar 2025 | SEK 37.2b | SEK 16.6b | SEK 614.3m | 38x | 60.5x | 2.2x |
| Wed, 19 Feb 2025 | SEK 44.0b | SEK 17.0b | -SEK 1,033,505,426.00 | 43.3x | -42.6x | 2.6x |
| Fri, 17 Jan 2025 | SEK 41.8b | SEK 16.7b | -SEK 1,152,911,426.00 | 43.4x | -36.3x | 2.5x |
| Sun, 15 Dec 2024 | SEK 44.1b | SEK 16.7b | -SEK 1,152,911,426.00 | 50.4x | -38.3x | 2.6x |
| Tue, 12 Nov 2024 | SEK 44.7b | SEK 16.8b | -SEK 948,072,426.00 | 50.9x | -47.1x | 2.7x |
| Thu, 10 Oct 2024 | SEK 47.1b | SEK 16.7b | -SEK 988,175,491.00 | 58.7x | -47.7x | 2.8x |
| Sat, 07 Sep 2024 | SEK 47.4b | SEK 16.7b | -SEK 988,176,492.00 | 59.9x | -48x | 2.8x |
| Mon, 05 Aug 2024 | SEK 47.4b | SEK 16.7b | -SEK 1,128,120,510.00 | 59.9x | -42x | 2.8x |
| Wed, 03 Jul 2024 | SEK 42.1b | SEK 16.3b | -SEK 1,188,686,510.00 | 54.3x | -35.4x | 2.6x |
| Fri, 31 May 2024 | SEK 42.3b | SEK 16.3b | -SEK 1,188,686,510.00 | 59.5x | -35.6x | 2.6x |
| Sun, 28 Apr 2024 | SEK 37.7b | SEK 16.2b | -SEK 1,246,589,705.00 | 36.2x | -30.2x | 2.3x |
| Tue, 26 Mar 2024 | SEK 39.7b | SEK 16.0b | -SEK 1,122,792,210.00 | 34.7x | -35.4x | 2.5x |
| Thu, 22 Feb 2024 | SEK 39.3b | SEK 16.2b | -SEK 1,117,407,350.00 | 43.4x | -35.2x | 2.4x |
| Sat, 20 Jan 2024 | SEK 35.8b | SEK 15.5b | -SEK 1,393,723,683.00 | 42.9x | -25.7x | 2.3x |
| Mon, 18 Dec 2023 | SEK 38.2b | SEK 15.5b | -SEK 1,393,723,683.00 | 47.6x | -27.4x | 2.5x |
| Wed, 15 Nov 2023 | SEK 32.6b | SEK 15.4b | -SEK 1,256,647,710.00 | 37.7x | -25.9x | 2.1x |
| Fri, 13 Oct 2023 | SEK 25.2b | SEK 15.1b | -SEK 1,134,516,711.00 | 35.7x | -22.2x | 1.7x |
| Sun, 10 Sep 2023 | SEK 29.2b | SEK 15.1b | -SEK 1,133,713,072.00 | 38.8x | -25.8x | 1.9x |
| Tue, 08 Aug 2023 | SEK 31.9b | SEK 15.1b | -SEK 213,871,038.00 | 46.3x | -149.2x | 2.1x |
| Thu, 06 Jul 2023 | SEK 36.6b | SEK 14.6b | -SEK 172,476,038.00 | 39x | -212.1x | 2.5x |
| Sat, 03 Jun 2023 | SEK 40.0b | SEK 14.6b | -SEK 173,602,038.00 | 39.5x | -230.2x | 2.7x |
| Mon, 01 May 2023 | SEK 36.4b | SEK 14.5b | -SEK 138,425,792.00 | 35x | -262.9x | 2.5x |
| Wed, 29 Mar 2023 | SEK 31.8b | SEK 14.6b | -SEK 57,185,459.00 | 31.1x | -556.2x | 2.2x |
| Fri, 24 Feb 2023 | SEK 38.4b | SEK 14.7b | -SEK 47,348,929.00 | 30.7x | -811.4x | 2.6x |
| Sun, 22 Jan 2023 | SEK 38.7b | SEK 14.2b | SEK 943.9m | 38.1x | 41x | 2.7x |
| Tue, 20 Dec 2022 | SEK 38.2b | SEK 14.1b | SEK 944.3m | 41.2x | 40.5x | 2.7x |
| Thu, 17 Nov 2022 | SEK 37.6b | SEK 14.1b | SEK 936.8m | 40.6x | 40.1x | 2.7x |
| Sat, 15 Oct 2022 | SEK 33.3b | SEK 13.5b | SEK 750.9m | 50x | 44.4x | 2.5x |
| Mon, 12 Sep 2022 | SEK 38.4b | SEK 13.5b | SEK 751.3m | 55.5x | 51.1x | 2.8x |
| Wed, 10 Aug 2022 | SEK 43.3b | SEK 13.2b | SEK 667.8m | 45.3x | 64.8x | 3.3x |
| Fri, 08 Jul 2022 | SEK 47.6b | SEK 13.2b | SEK 753.4m | 41.9x | 63.2x | 3.6x |
| Sun, 05 Jun 2022 | SEK 55.5b | SEK 13.2b | SEK 753.4m | 48.3x | 73.7x | 4.2x |
| Tue, 03 May 2022 | SEK 53.6b | SEK 12.7b | SEK 753.5m | 49.4x | 71.1x | 4.2x |
| Thu, 31 Mar 2022 | SEK 65.4b | SEK 11.8b | SEK 746.3m | 57.6x | 87.6x | 5.5x |
Price to Earnings Ratio
87.6x
Current Industry PE
- Investors are optimistic on the Swedish Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 60.5x which is higher than its 3-year average PE of -54.5x.
- The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.2x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have declined 6.3% per year over the last three years.
- Meanwhile revenues for these companies have grown 12% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Swedish Clinical Research and Equipment compare with similar industries?
| SE Market | -1.22% | |
| Healthcare | -0.24% | |
| Life Sciences | -2.18% | |
| Clinical Research and Equipment | -2.18% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AROC AroCell | SEK 0.53 | 3.9% +SEK 4.6m | 51.0% | PS2.1x | |
| ATANA Attana | SEK 0.007 | 16.7% +SEK 1.4m | -88.3% | PS1.5x |
